BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of $849.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-12-31 was -$4.07M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-09-30 was $3.72M, a 224.39% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-06-30 was $732.00K, a 584.11% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-03-31 was $467.00K.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was $849.00K.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2013 was -$817.00K.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2014-12-31 | -$4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$350.00K derived: sum of 2 quarters · filed 2015-11-02 | $382.00K derived: sum of 3 quarters · filed 2015-11-02 | $849.00K 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $3.72M 10-Q · filed 2015-11-02 | -$3.72M 10-Q · filed 2014-10-28 | $4.46M derived: sum of 2 quarters · filed 2015-11-02 | $4.92M 10-Q · filed 2015-11-02 | -$4.92M 10-Q · filed 2014-10-28 | $3.41M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2014-06-30 | $732.00K 10-Q · filed 2015-08-05 | -$732.00K 10-Q · filed 2014-07-31 | $1.20M 10-Q · filed 2015-08-05 | -$1.20M 10-Q · filed 2014-07-31 | -$311.00K derived: sum of 3 quarters · filed 2015-08-05 | $837.00K derived: sum of 4 quarters · filed 2015-08-05 | |
| 2014-03-31 | $467.00K 10-Q · filed 2015-05-05 | -$467.00K 10-Q · filed 2014-05-02 | -$1.04M derived: sum of 2 quarters · filed 2015-05-05 | $105.00K derived: sum of 3 quarters · filed 2015-05-05 | $212.00K derived: sum of 4 quarters · filed 2015-05-05 | ||
| 2013-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$362.00K derived: sum of 2 quarters · filed 2015-03-02 | -$255.00K derived: sum of 3 quarters · filed 2015-03-02 | -$817.00K 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $1.15M 10-Q · filed 2014-10-28 | $1.25M derived: sum of 2 quarters · filed 2014-10-28 | $693.00K 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | $107.00K 10-Q · filed 2014-07-31 | -$455.00K 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | -$562.00K 10-Q · filed 2014-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |